Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations

Elias Jabbour, Daniel Jones, Hagop M. Kantarjian, Susan O'Brien, Constantine Tam, Charles Koller, Jan A. Burger, Gautam Borthakur, William G. Wierda, Jorge Cortes

Research output: Contribution to journalArticle

Abstract

Secondary imatinib resistance in chronic myeloid leukemia (CML) is associated in approximately 50% of cases with mutations in the BCR-ABL kinase domain, necessitating switch to one of several new tyrosine kinase inhibitors (TKIs) that act differentially on mutated BCR-ABL. We assess here whether scoring mutation based on in vitro inhibitory concentration of each TKI-mutation pair can predict long-term clinical outcome. Among 169 patients with CML after imatinib failure, mutations were detected before TKI switch in 41 (48%) treated with dasatinib and 45 (52%) treated with nilotinib. Inhibitory concentration values for each TKImutation pair were stratified into high (n = 42), intermediate (n = 25), low (T315I, n = 9), or unknown sensitivity (n = 10). Hematologic and cytogenetic response rates were similar for patients with or without mutations. For patients in chronic phase, hematologic and cytogenetic responses correlated with mutation score; tumors with low and intermediate scores had lower response rates than those with highly sensitive mutations, and worse event-free and overall survival. These correlations with overall survival were not seen for advanced phases. Mutation scoring can predict outcome in CML-chronic phase with imatinib failure treated with second-generation TKIs and can help in therapy selection. More complex prognostic models will be required for advanced stages of disease.

Original languageEnglish (US)
Pages (from-to)2037-2043
Number of pages7
JournalBlood
Volume114
Issue number10
DOIs
StatePublished - Nov 20 2009
Externally publishedYes

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Protein-Tyrosine Kinases
Phosphotransferases
Mutation
Switches
Cytogenetics
Tumors
Leukemia, Myeloid, Chronic Phase
Imatinib Mesylate
In Vitro Techniques
Disease-Free Survival
Survival
Neoplasms

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations. / Jabbour, Elias; Jones, Daniel; Kantarjian, Hagop M.; O'Brien, Susan; Tam, Constantine; Koller, Charles; Burger, Jan A.; Borthakur, Gautam; Wierda, William G.; Cortes, Jorge.

In: Blood, Vol. 114, No. 10, 20.11.2009, p. 2037-2043.

Research output: Contribution to journalArticle

Jabbour, Elias ; Jones, Daniel ; Kantarjian, Hagop M. ; O'Brien, Susan ; Tam, Constantine ; Koller, Charles ; Burger, Jan A. ; Borthakur, Gautam ; Wierda, William G. ; Cortes, Jorge. / Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations. In: Blood. 2009 ; Vol. 114, No. 10. pp. 2037-2043.
@article{c6ac366e44854c959bcdfc4788afbb20,
title = "Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations",
abstract = "Secondary imatinib resistance in chronic myeloid leukemia (CML) is associated in approximately 50{\%} of cases with mutations in the BCR-ABL kinase domain, necessitating switch to one of several new tyrosine kinase inhibitors (TKIs) that act differentially on mutated BCR-ABL. We assess here whether scoring mutation based on in vitro inhibitory concentration of each TKI-mutation pair can predict long-term clinical outcome. Among 169 patients with CML after imatinib failure, mutations were detected before TKI switch in 41 (48{\%}) treated with dasatinib and 45 (52{\%}) treated with nilotinib. Inhibitory concentration values for each TKImutation pair were stratified into high (n = 42), intermediate (n = 25), low (T315I, n = 9), or unknown sensitivity (n = 10). Hematologic and cytogenetic response rates were similar for patients with or without mutations. For patients in chronic phase, hematologic and cytogenetic responses correlated with mutation score; tumors with low and intermediate scores had lower response rates than those with highly sensitive mutations, and worse event-free and overall survival. These correlations with overall survival were not seen for advanced phases. Mutation scoring can predict outcome in CML-chronic phase with imatinib failure treated with second-generation TKIs and can help in therapy selection. More complex prognostic models will be required for advanced stages of disease.",
author = "Elias Jabbour and Daniel Jones and Kantarjian, {Hagop M.} and Susan O'Brien and Constantine Tam and Charles Koller and Burger, {Jan A.} and Gautam Borthakur and Wierda, {William G.} and Jorge Cortes",
year = "2009",
month = "11",
day = "20",
doi = "10.1182/blood-2009-01-197715",
language = "English (US)",
volume = "114",
pages = "2037--2043",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "10",

}

TY - JOUR

T1 - Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations

AU - Jabbour, Elias

AU - Jones, Daniel

AU - Kantarjian, Hagop M.

AU - O'Brien, Susan

AU - Tam, Constantine

AU - Koller, Charles

AU - Burger, Jan A.

AU - Borthakur, Gautam

AU - Wierda, William G.

AU - Cortes, Jorge

PY - 2009/11/20

Y1 - 2009/11/20

N2 - Secondary imatinib resistance in chronic myeloid leukemia (CML) is associated in approximately 50% of cases with mutations in the BCR-ABL kinase domain, necessitating switch to one of several new tyrosine kinase inhibitors (TKIs) that act differentially on mutated BCR-ABL. We assess here whether scoring mutation based on in vitro inhibitory concentration of each TKI-mutation pair can predict long-term clinical outcome. Among 169 patients with CML after imatinib failure, mutations were detected before TKI switch in 41 (48%) treated with dasatinib and 45 (52%) treated with nilotinib. Inhibitory concentration values for each TKImutation pair were stratified into high (n = 42), intermediate (n = 25), low (T315I, n = 9), or unknown sensitivity (n = 10). Hematologic and cytogenetic response rates were similar for patients with or without mutations. For patients in chronic phase, hematologic and cytogenetic responses correlated with mutation score; tumors with low and intermediate scores had lower response rates than those with highly sensitive mutations, and worse event-free and overall survival. These correlations with overall survival were not seen for advanced phases. Mutation scoring can predict outcome in CML-chronic phase with imatinib failure treated with second-generation TKIs and can help in therapy selection. More complex prognostic models will be required for advanced stages of disease.

AB - Secondary imatinib resistance in chronic myeloid leukemia (CML) is associated in approximately 50% of cases with mutations in the BCR-ABL kinase domain, necessitating switch to one of several new tyrosine kinase inhibitors (TKIs) that act differentially on mutated BCR-ABL. We assess here whether scoring mutation based on in vitro inhibitory concentration of each TKI-mutation pair can predict long-term clinical outcome. Among 169 patients with CML after imatinib failure, mutations were detected before TKI switch in 41 (48%) treated with dasatinib and 45 (52%) treated with nilotinib. Inhibitory concentration values for each TKImutation pair were stratified into high (n = 42), intermediate (n = 25), low (T315I, n = 9), or unknown sensitivity (n = 10). Hematologic and cytogenetic response rates were similar for patients with or without mutations. For patients in chronic phase, hematologic and cytogenetic responses correlated with mutation score; tumors with low and intermediate scores had lower response rates than those with highly sensitive mutations, and worse event-free and overall survival. These correlations with overall survival were not seen for advanced phases. Mutation scoring can predict outcome in CML-chronic phase with imatinib failure treated with second-generation TKIs and can help in therapy selection. More complex prognostic models will be required for advanced stages of disease.

UR - http://www.scopus.com/inward/record.url?scp=70349245253&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349245253&partnerID=8YFLogxK

U2 - 10.1182/blood-2009-01-197715

DO - 10.1182/blood-2009-01-197715

M3 - Article

C2 - 19567878

AN - SCOPUS:70349245253

VL - 114

SP - 2037

EP - 2043

JO - Blood

JF - Blood

SN - 0006-4971

IS - 10

ER -